"Medical Speed Reader" rabies vaccine shortage Micro-medical plans to go to Hong Kong IPO in the third quarter of this year

Health Insurance Administration issues interim measures for the management of basic medical supplies for medical care; shortage of rabies vaccines in many places; IPO of micro-medicine in The Third Quarter of this year; Sanofi and Corning Jerry's strategic cooperation in research and development; insmedUS) brensocatib approved by FDA breakthrough therapy; Alnylam Pharmaceuticals is expected to be approved this year for RNAi therapyThe World Health Organization said on the 8th, the global new crown epidemic is worsening, in the past 10 days, 9 countries reported to the organization of new confirmed cases more than 100,000, 7 new cases are the highest since the outbreak22 (Xinhua) --continue to improve the level of rational use of antimicrobial drugs in order to implement in-depth the Opinions on Strengthening Drug Administration in Medical Institutions and promoting Rational Drug Use and the National Action Plan for Curbing Bacterial Resistance (2016-2020)The State Health and Care Commission issued a public consultation announcement on the notice (draft for comments) on the management of the clinical application of antimicrobial drugs under the new situation(National Health and Health Commission)the State Administration of Health Insurance issued the Interim Measures for the Administration of Medical Supplies for Basic Medical Insurance (Draft for Comments)The document clearly states that the administrative department of medical security under the State Council, taking into account the functional functions of medical supplies, clinical value, cost level, medical insurance fund affordability and other factors, adopted the access law to develop the "Basic Medical Supplies Directory" and regularly updated, dynamic adjustment(National Health Insurance Bureau)Jinhua City, Zhejiang Province, the Health Insurance Bureau issued "on the development of Jinhua City, the second batch of drug belt procurement announcement", has formed anti-infective primary research drugs, anti-infection non-primary research drugs and traditional Chinese medicine and other three preliminary catalog, a total of 274 product regulations for the deployment of band procurement(Jinhua City, Zhejiang Province)9, according to people familiar with the situation, Tencent investment in the online medical platform micro-medical plan in the third quarter to the Hong Kong Stock Exchange to raise $6-9 billion, the valuation of $5.5 billion, the previous round of financing is basically the same, the final financing scale will depend on market conditionsMicromedicine plans to hire Bank of China International, Citigroup and JPMorgan Chase as underwriters(Caixin.com)recently, Yunnan, Shanxi, Hebei, Anhui and other places have appeared rabies vaccine shortageAfter the outbreak of xinguan pneumonia, by the staff flow control, raw material transportation restrictions, epidemic prevention and control factors, enterprises in a long time failed to resume production, resulting in insufficient vaccine production Hengrui announced that it had agreed with Japan's Oncolyse to terminate the cooperation and signed a termination agreement in connection with Theanovirus Product TelomelysinTM (OBP-301) Following the termination of the partnership with Japan's Oncolyse, HengRui no longer owns the exclusive license for clinical development, production and commercialization of the ademotic virus product TelomelysinTM (OBP-301) in China and has discontinued research (Hengrui Pharmaceutical Announcement) Cinda Bio announced a strategic development partnership with Roche Group, covering multiple tumor cell therapy and bispecific antibodies This is the second large-scale foreign cooperation after two comprehensive cooperation signed by Cinda Bio and Lilly totalling more than $1.5 billion Cinda Bio has reached strategic cooperation with many well-known enterprises and research institutes both inside and outside China, including Huang Medicine, MicroCore Biology, Incyte, Adimab, etc Sanofi and Corning-Jerry announced that the two companies have signed an agreement to work together to advance clinical trials of KN026 and Tes®taxel's combination of drugs for HER2-positive breast cancer patients Under the terms of the agreement, Sanofi will have the right to negotiate an exclusive right to introduce KN026 within the exclusive period of time after reaching a specific clinical milestone Insmed, , has announced that the FDA has granted brensocatib (INS1007) breakthrough therapy eligibility for the treatment of adult non-cystic fibrosis bronchial dilation to reduce the risk of acute exacerbation of the lungs According to the Insight database, Cinda Bio's new class 1 drug, Injection IBI362, has launched a clinical trial for overweight or obese people (Pharma Rubik's Cube) Kanghong Pharmaceuticals announced that wholly-owned subsidiary Kanghong Bio and Mongolia's exclusive registration, distributor China International Medical and Health Co., Ltd recently received the Ministry of Health of Mongolia issued the Long Mu (Kompersip eye injection) drug registration certificate (registration certificate number: FT20200221SH07461) (Pharmaceutical Rubik's Cube) Yiling Pharmaceuticals issued a notice that its application for registration of new drugs for the puzzle-an god tablets has been formally accepted by the State Drug Administration Yizhi An God tablet is the company based on the Chinese network health eight-word theory to guide insomnia machine treatment of the development of new Chinese medicine (Toling Pharmaceuticals Announcement) East China Pharmaceuticals issued an announcement, its wholly-owned subsidiary Xi'an Bohua production of dopone ketone tablets (10mg) through the generic drug consistency evaluation, for the species of the third domestic evaluation of the enterprise (Insight Database) Astellas recently released positive results from the Phase III DOLOMITES study The study was conducted in adult patients with non-dialysis dependence (NDD) stage 3-5 chronic kidney disease (CKD) and assessed the efficacy and safety of Evrenzo (Chinese commodity name: Erizo, generic name: roxadustat, Rosasta) and Darbepoetin alfa to treat anemia The data showed that Evrenzo was not bad at daipoin alpha when it was corrected for hemoglobin levels during the first 24 weeks of treatment (Bio Valley) recently, Concord Fermentation Kirin Co., Ltd Dayipotin alpha injection application (JXSS190005/6/7/8/9) in nMPA status changed to "in approval." (CPhI Pharmaceuticals Online) , Alnylam Pharmaceuticals announced that positive results have been obtained in the phase 3 clinical trial of LUMINATE-A in the treatment of type 1 primary hypergrassyotic acid (PH1) in the study of RNAi therapy lumasiran This one has been granted FDA priority review status by the research therapy Jetbellin recently announced the results of a Phase II clinical trial of Garadacimab (formerly known as CSL312) The drug is a new type of factor XIIa inhibitory monoclonal antibody (FXIIa-mAb) used as a preventive therapy for hereditary angioedema (HAE) The incidence of garadacimab treatment group decreased significantly compared to placebo Studies have also shown that garadacimab has good tolerance (Bio Valley)